Bisphosphonate Drug Holiday and Fracture Risk: Reviewing the Evidence

被引：0
作者：
Annette L. Adams
Denison S. Ryan
Anna Lawless
Heidi Fischer
机构：
[1] Kaiser Permanente Southern California,Department of Research & Evaluation
来源：
Current Treatment Options in Rheumatology | 2022年 / 8卷
关键词：
Bisphosphonates; Drug holiday; Osteoporosis treatment; Fracture;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：37 / 55
页数：18
相关论文
共 222 条
  • [41] Burr D(2011)An introduction to propensity score methods for reducing the effects of confounding in observational studies Multivariate Behav Res 46 399-30
  • [42] Ebeling PR(2016)Using big data to emulate a target trial when a randomized trial is not available Am J Epidemiol 183 758-1743
  • [43] Abrahamsen B(2019)Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline J Clin Endocrinol Metab 104 1595-325
  • [44] Adler RA(2017)Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement Maturitas 101 23-undefined
  • [45] Brown TD(2019)Fracture risk following intermission of osteoporosis therapy Osteoporos Int 30 1733-undefined
  • [46] Shane E(2015)Residual effect after oral bisphosphonate treatment and healthy adherer effects–the Swedish Adherence Register Analysis (SARA) Osteoporos Int 26 315-undefined
  • [47] Burr D(undefined)undefined undefined undefined undefined-undefined
  • [48] Abrahamsen B(undefined)undefined undefined undefined undefined-undefined
  • [49] Adler RA(undefined)undefined undefined undefined undefined-undefined
  • [50] Brown TD(undefined)undefined undefined undefined undefined-undefined
12345678910